Tele No.011-23236965
Fax.No.011-23236973

F. No. 12-04/19-DC
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:
25 AUG 2020

To
M/s Dystrophy Annihilation Research Trust,
295, 14th cross, Dollars colony, RMV II stage,
Sanjay Nagar, Bangalore, India – 560094.

Subject:- Permission for conducting clinical study entitled, "A Double Blind, Placebo-Controlled, Multicentre Study with an Open-Label Extension to Evaluate the Efficacy and Safety of 2'O Methyl Antisense Oligonucleotide in Patients with Duchenne Muscular Dystrophy" - regarding.

Sir,

With reference to your application No. nil dated 01.07.2020, please find enclosed herewith the permission in Form CT-06, No. **CT/ND/79/2020** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully

(Dr. V. G. Somani)
Central Licensing Authority

Condition of permission

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under Rule 8;

(ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority;

(ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;

(x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

(xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;

(xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licensing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits M/s Dystrophy Annihilation Research Trust, #295, 14th cross, Dollars colony, Sanjay Nagar, Bangalore, India – 560094, Tel: +91 80 23412725, Mob: +91 9840219833, +91 9880112725 to conduct clinical trial of the investigational new drug as per **Protocol No. DART_CT_DMD-01, version 03 dated 15.06.2020** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:-

Names of the new drug or investigational new drug:	2'O-Methyl-Phosphothioate Anti Sense ribonucleotide (2'OMePS RNA)
Therapeutic class:	Antisense oligonucleotide
Dosage form:	Lyophilized powder for Intravenous (IV) injection, to be reconstituted in aqueous phosphate buffer Saline
Composition:	Each Lyphophilised vial contains- 100 mg of 2'O Methyl Phosphothioate Antisense ribonucleotide (2'OMePS RNA)
Indications:	Duchenne muscular dystrophy (DMD)

Details of clinical trial sites-

Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
01	Dr. G.N Sanjeeva Indira Gandhi Institute of Child Health, 1st Block, Siddapura, Jayanagar, Bengaluru, Karnataka 560029	Ethics Committee, Indira Gandhi Institute of Child Health, South Hospital Complex, Dharmaram, College Post Bengaluru, Karnataka 560029 ECR/441/Inst/KA/2013/RR-16
02	Dr. I C Verma Sir Ganga Ram Hospital Sarhadi Gandhi Marg, near Bal Bharati Public School, Old Rajinder Nagar, Rajinder Nagar, New Delhi, Delhi 110060	Ethics Committee, Sir Gangaram Hospital Old Rajinder Nagar, New Delhi, 110060 ECR/20/Inst/DL/2013/RR-19
03	Dr.Madhulika Kabra All India Institute of medical Sciences Sri Aurobindo Marg, Ansari Nagar, Ansari Nagar East, New Delhi, Delhi 110029	Institute Ethics Committee, All India Institute of medical Sciences, Old OT Block, Room No:102, AIIMS Hospital, Ansari Nagar, New Delhi, 110029 ECR/538/Inst/DL/2014/RR-20

04	Dr. Renu Suthar Postgraduate Institute of Medical Education & Research Madhya Marg, Sector 12, Chandigarh, 160012	Institutional Ethics Committee, Postgraduate Institute of Medical Education & Research, Room No:6006, IEC Office, 6th Floor, PN Chuttani Block Chandigarh, 160012 ECR/25/Inst/CH/2013/RR-20
05	Dr. Ashok Gupta SMS Medical College Gangawal Park, Adarsh Nagar, Jaipur, Rajasthan 302004	Ethics Committee, SMS Medical College and attached Hospital, JLN Marg, Jaipur, Rajasthan 302004 ECR/26/Inst/RJ/2013/RR-19
06	Dr.Bhavna Dhingraa Bhan All India Institute of medical Sciences Saket Nagar, AIIMS Campus, Bagh Swaniya, Bhopal, Madhya Pradesh 462020	Institutional Human Ethics Committee, All India Institute of medical Sciences, Dept of Biochemistry Block, Ground Floor, Medical College Builiding, Saket Nagar, Bhopal, Madhya Pradesh 462024 ECR/775/Inst/MP/2015
07	Dr. Ashka Prajapati CIMS Hospital Science City Rd, Science City, Panchamrut Bunglows II, Sola, Ahmedabad, Gujarat 380060	Ethics committee of CIMS Care Institute of Medical Sciences, Nr Shukan Mall of Science City Rd, Sola, Ahmedabad, Gujarat 380060 ECR/206/Inst/GJ/2013/RR-20
08	Dr. Abhijeet Botre KEM Hospital 489, Sardar Mudaliar Road, Rasta Peth, Pune, Maharashtra 411011	KEM Hospital Research Centre Ethics Committee, KEM Hospital research Centre, TDH Building, Rasta Peth, III Floor, 303, Pune, Maharashtra 411011 ECR/272/Inst/MH/2013/RR-19
09	Dr.Prajnya Ranganath Nizam's Institute of medical Sciences Punjagutta Rd, Punjagutta Market, Punjagutta, Hyderabad, Telangana 500082	NIMS Institutional Ethics Committee, Nizam's Institute of medical Sciences, Punjagutta, Hyderabad, Telangana 500082 ECR/303/Inst/AP/2013/RR-19

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

(Dr. V. G. Somani)
Central Licensing Authority
Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

New Delhi
Date: .....
25 AUG 2020